Summary
Edwards Lifesciences Corporation (EW) reported its second quarter and year-to-date results for the period ending June 30, 2022. While overall net sales saw a slight increase of 4.7% to $2.7 billion for the first six months of the year, driven by Transcatheter Aortic Valve Replacement (TAVR) products, the company faced headwinds in the second quarter. Net sales for the three months ended June 30, 2022, were essentially flat year-over-year at $1.37 billion, impacted by slower-than-expected improvement in US hospital staffing and unfavorable foreign currency exchange rates. Despite these challenges, the company demonstrated strong operational execution, with gross profit increasing due to sales growth and a positive impact from its foreign currency hedging program. However, diluted earnings per share saw a decline for the six-month period, largely attributed to changes in the fair value of contingent consideration liabilities and increased operating expenses related to sales, marketing, and R&D investments. The company continues to invest heavily in innovation, particularly in its TAVR and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments, with significant clinical trial activity underway. Management remains confident in its liquidity and ability to fund its operations and strategic initiatives, including a substantial ongoing share repurchase program.
Financial Highlights
50 data points| Revenue | $1.37B |
| Cost of Revenue | $269.40M |
| Gross Profit | $1.10B |
| R&D Expenses | $250.80M |
| SG&A Expenses | $409.00M |
| Operating Income | $459.50M |
| Net Income | $406.40M |
| EPS (Basic) | $0.65 |
| EPS (Diluted) | $0.65 |
| Shares Outstanding (Basic) | 620.90M |
| Shares Outstanding (Diluted) | 626.70M |
Key Highlights
- 1Net sales for the six months ended June 30, 2022, increased by 4.7% to $2.72 billion, primarily driven by TAVR product sales.
- 2The company experienced flat net sales for the three months ended June 30, 2022 ($1.37 billion), impacted by US hospital staffing shortages and unfavorable foreign currency movements.
- 3Gross profit increased for the six months ended June 30, 2022, benefiting from sales growth and the positive impact of foreign currency hedging.
- 4Diluted earnings per share decreased for the six months ended June 30, 2022, due to changes in fair value of contingent consideration liabilities and increased operating expenses.
- 5Research and Development expenses increased in the first half of 2022, reflecting continued investment in transcatheter innovations and clinical trials.
- 6The company repurchased $746.4 million of its common stock during the first six months of 2022 and announced an additional $1.5 billion repurchase authorization.
- 7Edwards Lifesciences is actively engaged in pivotal trials for next-generation TAVR technologies and expansion of its TMTT offerings, including PASCAL Precision and EVOQUE systems.